The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis

NCT07371572 · tracked via the Priya Life Science Netherlands tracker

Sponsor

Sint Maartenskliniek

Phase

Phase 3

Started

2025-10-28

Last updated

2026-01-28

Condition(s) studied

Hand Osteoarthritis

Investigational drug(s) / intervention(s)

120mg methylprednisolone acetate →40mg methylprednisolone acetate →Placebo

120mg methylprednisolone acetate: One single intramuscular injection with 120mg methylprednisolone will be administered at baseline to each participant in the first phase. During the second phase, participants may receive intramuscular methylprednisolone on demand at the dosage of 120mg only if they fulfil the following conditions: hand pain \>30mm on a VAS (0-100mm) and a minimum of 16 weeks interval between two consecutive injections.

40mg methylprednisolone acetate: One single intramuscular injection with 40mg methylprednisolone will be administered at baseline to each participant in the first phase.

Placebo: One single intramuscular injection of placebo (NaCl 0.9%) will be administered at baseline to each participant in this phase.

Study summary

The goal of this clinical trial is to determine the efficacy and safety of intramuscular methylprednisolone in patients with hand osteoarthritis. The main question it aims to answer is what the difference is in hand pain 4 weeks after the first injection with methylplrednisolone. This main goal will be assessed in the first 16 weeks, the RCT phase. Researchers will compare 120mg methylprednisolone with 40mg methylprednisolone and placebo to see if there is a difference in hand pain after 4 weeks.

Participants will be asked to visit the hospital for:

* injection of the study material
* ultrasound assessment
* physical examination like joint assessments and grip strenght
* examination of blood
* x-ray of the hand

In phase 2, from week 16 to 48, an open label phase focusing on treatment strategy and safety. In this phase all participants may receive intramuscular methylprednisolone on demand at the dosage of 120mg only if they fulfil the following conditions: hand pain \> 30mm on a VAS (0-100mm) and a minimum of 16 weeks interval between two consecutive injections. Therefore, a maximum of two injections could be received during this period. Irrespective of that, all participants will be followed-up until week 48 when the end-of-study visit will take place.

Eligibility

Sex

ALL

Min age

16 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients with interphalangeal hand OA (according to the EULAR classification criteria 2023) based on patient report (age, morning stiffness) and radiographs of ≤6 months old (osteophytes, JSN (joint space narrowing) and symptom-structure concordance (present if majority (≥50%) of the symptomatic joints demonstrate radiographic findings)). * Age ≥ 16 years * Have hand pain \>40mm on a 100mm visual analogue scale (VAS) * Have previously experienced failure of at least one conventional type of pain medication, (self-reported of insufficient effect from topical or oral NSAID, etc. with exclusion of paracetamol) Exclusion Criteria: * Comorbidity * Chronic inflammatory (rheumatic) diseases * Infectious diseases * Known Osteoporosis * Known Diabetes * Previous diagnosis of fibromyalgia * Known myasthenia gravis * Previous surgical interventions on the hand (e.g. carpal tunnel syndrome, etc.) * Use of other Medication: In order to maximize the generalizability of the study interactions between methylprednisolone and co-medication is only prohibited when the Dutch Medication Surveillance System (Z-index) gives a signal for this interaction. * Patients with a contraindication for MP * Current Gastric and duodenal ulcers * Current infections * Liver cirrhosis * Pregnant or breastfeeding * Known non-response or intolerance for MP * Not able to read or write the Dutch language * Neurological diagnosis * Epilepsy * Risk of psychiatric disorder

Primary outcome measure(s)

Efficacy of intramuscular methylprednisolone acetate in reducing hand pain between baseline and week 4, compared to placebo measured on a 0-100 mm Visual Analogue Scale — From baseline to week 4
The primary objective of this study is to assess the efficacy of intramuscular methylprednisolone acetate (120mg or 40mg) in reducing hand pain between baseline and week 4, compared to placebo measured on a digital Visual Analogue Scale ranging from 1-100 mm. The higher the score, the worse the outcome.

Trial sites (1)

Facility	City	Region	Status
Sint Maartenskliniek	Ubbergen	Gelderland	Recruiting

More Sint Maartenskliniek trials in the Netherlands

REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases Recruiting

Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse Active, not recruiting

Discontinuation of Disease-modifying Anti-rheumatic Drugs (DMARDs) in Rheumatoid Arthritis Patients Also Using TNF Inhibitors Recruiting

TrEatment Targets in Rheumatoid Arthritis: TETRA-study Active, not recruiting

The Effect of ColcHicine on the Incidence of Knee or Hip Replacements Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07371572 on ClinicalTrials.gov ↗ ← All trials in the Netherlands